Olaparib CAS 763113-22-0

Pwodwi deskripsyon

Non pwodwi: Olaparib CAS non: 763113-22-0

 

 

Synonyms:

1 (2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl) -1-piperazinyl] carbonyl] -4-fluorophenyl] méthyle]-;

1-(Cyclopropylcarbonyl)-4-[5-[(3, 4-dihydro-4-oxo-1-phthalazinyl) méthyle] -2-fluorobenzoyl] piperazine;

AZD-2281; AZD2281;

azd2281 Olaparib;

4-(3-{[4-(Cyclopropylcarbonyl) -1-piperazinyl] carbonyl} -4-fluorobenzyl)-1 (2H)-phthalazinone;

Olaparib; Lynparza;

4-(3-{[4-(Cyclopropylcarbonyl) piperazin-1-yl] carbonyl} -4-fluorobenzyl) phthalazin-1 (2H)-youn;

 

 

Chimik & pwopriyete fizik

Aparans: blan solid.

Épreuves: ≥ 99,5%

Dansite: 1.43 g/cm3

 

 

Olaparib (AZD-2281, non komes Lynparza) se yon terapi ki te apwouve FDA pou kanse, devlope pa KuDOS edikaman ak pita pa AstraZeneca. Li se yon "PARINIBITE, anpeche Poly ADP ribose polimerizasyon (PARP), yon anzim ki enplike nan reparasyon ADN. Li aji kont kanse nan moun ki gen fanmilyal BRCA1 oswa BRCA2 mitasyon, ki gen ladan kek ovarian, tete, ak pwostat kanse. An desanm 2014, olaparib te apwouve pou itilize kom yon ajan sel pa EMA la ak FDA a. Apwobasyon FDA a se nan pou germline BRCA mutated (gBRCAm) ovarian kanse ki te resevwa twa oswa plis anvan liy nan chimyoterapi.

 

 

Si ou enterese nan pwodwi nou yo oswa gen nenpot kesyon, tanpri santi yo lib yo kontakte nou!

 

 

Pwodwi anba patant yo ofri pou R & D objektif selman. Sepandan, responsablite final la manti selman avek achte a.

Baj popilè: olaparib cas 763113-22-0, manifaktire, founise, faktori, achte, nan Stock

• On: 1 ((Cyclopropylcarbonyl) piperazine Hydrochloride CAS NO: 1021298-67-8
• Pwochen: 3- (2-chloropyrimidin-4-y) -1-methylindole CAS 1032452-86-0